Kura Oncology

• Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  Phase 3, Recruiting, 1,300 people, 5 Jun 2025

• NCT06930352

  Collaborator, Phase 2, Recruiting, 70 people, 16 Apr 2025

• NCT06655246

  Phase 1, Recruiting, 157 people, 23 Oct 2024

• NCT06448013

  Collaborator, Phase 1, Recruiting, 22 people, 7 Jun 2024

• NCT06397027

  Collaborator, Phase 1, Recruiting, 22 people, 2 May 2024

• NCT05848687

  Collaborator, Phase 1/2, Recruiting, 90 people, 8 May 2023

• NCT05735184

  Phase 1, Recruiting, 420 people, 21 Feb 2023

Sources: clinicaltrials.gov

• Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s)

  Fees or honoraria, Grants or research support, 28 Sept 2026

• Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

  Consulting or advice, Fees or honoraria, Grants or research support, Board or leadership role, 12 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov